Member Info for Lionel1

Just catching up, 0.75 , my goodness , shame on you Gino and the crew .

What a sad state of affairs , I would fire the entire sales team if there is one.

I never thought this would go under 1 P , well done BOD .. very nicely orchestrated.. now I see what they want .

@Jimi , forget about new tests . Let them sell this first .. I see 4 employees left in past 8 weeks , I wonder what’s going on .

Amer , it’s a virus fully infected .. he will not leave until he gets his 200£ back , Unless we mass report this idiot .

bunch of clowns running this company , great products and **** show …

I think some of us missing key points , I have asked chat got for real world scenarios for Genedrive tests .

Genedrive isn’t replacing lab tests — it’s solving a problem labs can’t solve:

Delivering critical genetic information before treatment starts — especially when treatment can’t wait.

Real-World Clinical Scenarios

1. Newborns with Suspected Sepsis (MT-RNR1)

• Clinicians must give antibiotics within 1 hour of birth.

• Standard lab test takes >24 hours, so the baby gets gentamicin — risking permanent deafness if genetically susceptible.

• Genedrive provides a result in 26 minutes, before the antibiotic is given.

👉 This is not about replacing the lab — it’s about being in time to prevent damage.

⸻

2. Stroke Patients (CYP2C19-ID)

• Time is brain. Clopidogrel is often given quickly in TIA/stroke.

• If the patient is a poor metaboliser (30% of UK population), the drug is ineffective, leading to a second stroke.

• A lab test takes days — by then, damage is done.

• Genedrive gives a result in ~70 minutes at the bedside — allows switching to ticagrelor immediately.

Hospitals can’t wait days when a patient needs treatment now.

I never binned anyone so far , but EC you are unbelievable.. stop the nonsense man .

@Mikodx , I know you from ODX board :-) , if you are 90% down on GDR then there is no point selling now .. wait for couple of years if you want to get out with true value for your investment.

Very good for firms like Genedrive .

https://www.gov.uk/government/news/life-sciences-sector-plan-to-grow-economy-and-transform-nhs

The article says ,

Testing now includes all babies in neonatal units, not just those in intensive care.

Due to this success, a new UK-wide study (PALOH-UK) began in November 2024, expanding the testing to 14 neonatal units across England, Scotland, Wales, and Northern Ireland.

In short, incorporating in Northern Ireland can be a strategic move tied to legal, regulatory, tax, or market-access considerations.

They must be very close to good business with Europe .

Chat GPT says :

Access to Both UK and EU Markets (Post-Brexit Factor)

• Under the Windsor Framework (successor to the NI Protocol), Northern Ireland has a special status allowing goods to move freely into the EU single market for goods, while still being part of the UK’s customs territory.

• Businesses dealing with cross-border trade (especially with Ireland/EU) may incorporate in Northern Ireland to benefit from smoother regulatory treatment.

Https://healthinnovationmanchester.com/news/health-innovation-manchester-celebrates-the-success-of-groundbreaking-genetic-test-preventing-newborn-hearing-loss/

Https://find-and-update.company-information.service.gov.uk/company/NI731212

Incorporation date 8th July 2025 .

New company ???

What’s coming ???

https://www.linkedin.com/posts/genedrive-plc_gdr-activity-7348008603653402624-yMC4?utm_medium=ios_app&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY&utm_source=social_share_send&utm_campaign=copy_link

I think they said few times before , De Novo route application and they will be submitting mid to late 2025 , can you share the slide where they said end of fy26 ??

Good one Stephen .

Genedrive is at the right place with right tests , now it’s upto the BOD how they promote and sell these tests .

https://www.nature.com/articles/s41397-025-00375-0

https://www.acsh.org/news/2025/06/24/how-genetic-testing-could-prevent-dangerous-drug-reactions-and-reduce-healthcare

Https://med-techinsights.com/2025/06/25/opening-the-nhs-to-innovation-a-procurement-perspective/

ChatGPT says ..

As of now, Genedrive has not officially launched the novel RT-qPCR assay for Crimean–Congo hemorrhagic fever virus (CCHFV) described in the recent preprint. The publication, titled “Development and Evaluation of a Novel RT‑qPCR Assay for Detection…”, was released just three days ago and is currently in the peer-review process. There is no indication that the assay has received regulatory approval or is commercially available at this time.()

Genedrive’s current product offerings, such as the Genedrive® CYP2C19 ID Kit, are focused on pharmacogenetic testing and are CE-marked under the European In Vitro Diagnostics Regulation. These products are designed for use in time-critical settings to improve clinical outcomes. 

The CCHFV RT-qPCR assay, developed in collaboration with the Liverpool School of Tropical Medicine, is a novel diagnostic tool aimed at enhancing point-of-care detection capabilities for CCHFV. Its development is part of ongoing research efforts to improve diagnostics for emerging infectious diseases.()